Who founded Nanopath?

Nanopath was founded by Alison Burklund, Amogha Tadimety in 2019.

Who are Nanopath's investors?

Nanopath's investors include Norwest Venture Partners, Service Provider Capital, Gingerbread Capital, Medtech Convergence, Norwich Ventures.

How much funding has Nanopath raised?

Nanopath has disclosed $15.3M raised across 2 rounds.

Where is Nanopath headquartered?

Nanopath is headquartered in Cambridge, US.

Nanopath

Cambridge, US · Founded 2019 · Delaware corporation · 29 employees on LinkedIn · 5 known investors

Nanopath is developing a molecular diagnostic platform for point-of-care disease diagnosis, with a focus on women's health. The company builds novel diagnostic technologies aimed at scalable, accessible testing.

Biotech FemTech Medical Devices

Founders & leadership

Nanopath was founded in 2019 by Alison Burklund and Amogha Tadimety.

Alison BurklundinCo-founder30 Under 30 2023

Amogha TadimetyinCo-founder

Board

Aaron Sandoski inBoard directorMCF Partner at SV Health Investors

Jeff CroweBoard director

Investors · 5

Norwest Venture PartnersMenlo Park · $10M – $30M

Service Provider CapitalVail

Gingerbread CapitalreportedNew York · $100K – $10M

Medtech ConvergencereportedBoston

Norwich VenturesreportedWalthamvia Aaron Sandoski · board

Reported raises · per SEC filings

Form D private placements

$15.3M disclosed across 2 rounds · 2022–2025

▶$5.3MraisedFeb 2025 · 5 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Alison BurklundExecutive Officer, Director
Aaron SandoskiDirector
Amogha TadimetyExecutive Officer, Director
Jeff CroweDirector

Offering amount: $6M
Amount sold: $5.3M
First sale: Jan 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$10MraisedAug 2022 · 10 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Jeffrey CroweDirector
Alison BurklundExecutive Officer, Director
Amogha TadimetyExecutive Officer, Director

Offering amount: $10M
Amount sold: $10M
First sale: Jun 2022
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Nanopath Expands Leadership Team to Drive Next Phase of Scientific and Commercial Growthprnewswire.com · Oct 2025

Nanopath Receives $4M in Grantsfinsmes.com · May 2024

Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundationprnewswire.com · May 2024

Nanopath Raises $10M in Series A Fundingfinsmes.com · Aug 2022

Nanopath raises $10M Series A for women's health diagnosticsmassdevice.com · Aug 2022

Nanopath Secures $10 Million in Series A Funding to Develop and Commercialize Point-of-Care Diagnostics for Women's Healthprnewswire.com · Aug 2022

Frequently asked questions

What does Nanopath do?: Nanopath is developing a molecular diagnostic platform for point-of-care disease diagnosis, with a focus on women's health. The company builds novel diagnostic technologies aimed at scalable, accessible testing.
Who founded Nanopath?: Nanopath was founded by Alison Burklund, Amogha Tadimety in 2019.
Who are Nanopath's investors?: Nanopath's investors include Norwest Venture Partners, Service Provider Capital, Gingerbread Capital, Medtech Convergence, Norwich Ventures.
How much funding has Nanopath raised?: Nanopath has disclosed $15.3M raised across 2 rounds.
Where is Nanopath headquartered?: Nanopath is headquartered in Cambridge, US.